Everything you need to win Molecular Partners AG — in one platform.
Who to reach, what to say, and why now on Molecular Partners AG — plus every funding round, exec hire, and M&A move that follows, each with the verified contact and the outreach written for you.
Get the full Deep Dive on Molecular Partners AG — free.
One free Deep Dive, emailed to you. No spam; unsubscribe anytime.
The decision-maker’s email and mobile — dial in-browser.
Molecular Partners and Orano Med Strengthen Co-Development Agreement for Radio-DARPin Therapeutics
Oct 22, 2024•over 1 year ago
Contract Type
agreement
BiotechnologyTherapeuticsBiopharma
Description
Molecular Partners AG and Orano Med have strengthened their co-development agreement to include the co-development and commercialization of four Radio-DARPin programs. Each company will have the right to commercialize two of the programs, and Molecular Partners will hold commercial rights to the second nominated Radio-DARPin Candidate. The collaboration aims to develop and market Pb-based Radio-DARPin Therapeutics for the treatment of cancer.
Company Information
Company
Molecular Partners AG
About
Molecular Partners AG is a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics.
Predictive Intelligence
Strategic
ML-powered predictions for Molecular Partners AG's next move
